Evaluating the Cutaneous Pharmacokinetics of Topical Drug Products Using Pharmacokinetic Tomography (U01 Clinical Trial Required)

Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional

This grant aims to improve prediction of food/drug interactions for high-risk oral drugs by using a lab model that mimics the gut to assess drug performance.

HHS-FDA$500,000Forecasted

Developing PBPK Model-Based Mechanistic IVIVCs for Long Acting Injectable Suspensions and Implants (U01) Clinical Trial Optional

This grant aims to create PBPK models for long-acting injectable suspensions and implants, predicting drug release by linking formulation attributes to in-vivo performance.

HHS-FDA$300,000Forecasted

Utilizing Real-World Data and Algorithmic Analyses to Assess Post-Market Clinical Outcomes in Patients Switching Amongst Therapeutically Equivalent Complex Generic Drug Products and Reference Listed Drugs (U01) Clinical Trial Not Allowed

This grant seeks to develop AI/ML models using real-world data to monitor clinical outcomes when patients switch between complex generics and brand-name drugs.

HHS-FDA$300,000Forecasted

Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)

NIH will fund investigator-initiated multi-site or decentralized clinical trials relevant to its mission, supporting planning and implementation over up to 7 years using a milestone-driven UG3/UH3 grant mechanism.

HHS-NIH11Forecasted Feb 16, 2027Forecasted

Forecast for Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed)

This upcoming NIH grant will fund innovative preclinical research to develop new methods or agents that selectively target "undruggable" molecules involved in difficult-to-treat human diseases.

HHS-NIH11Due Jan 18, 2027$275,000